Spikevax Bivalent Original/Omicron Ba.4-5

Spikevax Bivalent Original/Omicron Ba.4-5 vaccine is designed to protect against COVID-19 by targeting both the original virus strain and Omicron subvariants Ba.4 and Ba.5. This bivalent formulation enhances immune response for broader coverage. It is administered via intramuscular injection and is authorized for use in eligible populations.

Spikevax Bivalent Original/Omicron Ba.4-5 is used to help prevent COVID-19 infection caused by SARS-CoV-2, including the original strain and Omicron variants Ba.4 and Ba.5. It is intended for individuals who meet eligibility criteria set by health authorities. The vaccine works by prompting the immune system to recognize and respond to the virus.

After administration, the vaccine may cause temporary local reactions such as pain, redness, or swelling at the injection site. Some individuals may experience general effects like fatigue, headache, muscle pain, or mild fever. These effects are typically mild to moderate and resolve within a few days.

Store the vaccine between 2°C and 25°C (36°F and 77°F) and protect it from light. Do not freeze. Handle with care to avoid contamination or damage. Ensure proper disposal of used syringes and needles in accordance with local regulations. Consult a healthcare provider if you have a history of severe allergic reactions.

No specific drug interactions have been established for Spikevax Bivalent. However, like all vaccines, it should be administered with caution in individuals receiving immunosuppressive therapies. Avoid concurrent administration with other vaccines in the same limb. Always inform your healthcare provider about any medications or treatments you are currently using.